A study on treatment switch to epoetin beta pegol in patients who do not respond well to erythropoietin preparation - A study on treatment switch to epoetin beta pegol in patients who do not respond well to ESA

Faculty of medicine, University of Miyazaki0 个研究点目标入组 5 人开始时间: 2012年6月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with iron deficiency Patients who have uncontrollable hypertension Patients with heart failure (NYHA functional class 3or 4) Women who are pregnant, breastfeeding, or possibly pregnant. Patients who have known serious allergy or serious drug allergy (shock, anaphylactoid symptoms) Patients who have malignant tumor (including hematologic malignancy), severe infection, systemic hematologic disease (e.g. myelodysplastic syndrome, hemoglobinopathy), hemolytic anemia, or apparent hemorrhagic lesion such as gastrointestinal bleeding Patients who have received CERA before enrollment Patients whose AST or ALT level was100 IU/L or higher in the latest examination before enrollment Patients who received red blood cell transfusion within 16 weeks prior to enrollment Patients who are scheduled for surgery that may cause massive bleeding during the study period Patients who are judged ineligible by the investigator/sub-investigator

发起方

Faculty of medicine, University of Miyazaki